The development of a regional referral pathway for locally recurrent rectal cancer: A Delphi consensus study.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
03 2020
Historique:
received: 18 07 2019
revised: 18 11 2019
accepted: 01 12 2019
pubmed: 24 12 2019
medline: 21 10 2020
entrez: 24 12 2019
Statut: ppublish

Résumé

The management of patients with locally recurrent rectal cancer (LRRC) is often complex and requires multidisciplinary input whereas only few patients are referred to a specialist centre. The aim of this study was to design a regional referral pathway for LRRC, in Nouvelle Aquitaine (South-West, France). In 2016, we conducted with a Study Steering Committee (SC) a three phase mixed-methods study including identification of key factors, identification of key stakeholders and Delphi voting consensus. During three rounds of Delphi voting, a consensus was defined as favorable, if at least 80% of participating experts rate the factor, below or equal to 3/10 using a Likert scale, or consider it as "useful" using a binary scale (third round only). Finally, the SC drafted guidelines. Among the 423 physicians involved in 29 regional digestive Multi-Disciplinary Team (MDT) meeting, 59 participants (from 26 MDT meeting) completed all three rounds of Delphi voting. Thirteen out of twenty initially selected factors reached a favorable consensus. All patients with a LRRC need to be included into a referral pathway. Patients with a central pelvic recurrence offered curative treatment in their local hospital and patients with unresectable metastatic disease were excluded of the referral. Key performance indicators were also agreed including the time to referral and completion of pelvic MRI-, CT-, PET-scan prior to MDT referral. The development of this referral pathway represents an innovative health service, which will improve the management of patients with LRRC in France.

Sections du résumé

BACKGROUND
The management of patients with locally recurrent rectal cancer (LRRC) is often complex and requires multidisciplinary input whereas only few patients are referred to a specialist centre. The aim of this study was to design a regional referral pathway for LRRC, in Nouvelle Aquitaine (South-West, France).
METHODS
In 2016, we conducted with a Study Steering Committee (SC) a three phase mixed-methods study including identification of key factors, identification of key stakeholders and Delphi voting consensus. During three rounds of Delphi voting, a consensus was defined as favorable, if at least 80% of participating experts rate the factor, below or equal to 3/10 using a Likert scale, or consider it as "useful" using a binary scale (third round only). Finally, the SC drafted guidelines.
RESULTS
Among the 423 physicians involved in 29 regional digestive Multi-Disciplinary Team (MDT) meeting, 59 participants (from 26 MDT meeting) completed all three rounds of Delphi voting. Thirteen out of twenty initially selected factors reached a favorable consensus. All patients with a LRRC need to be included into a referral pathway. Patients with a central pelvic recurrence offered curative treatment in their local hospital and patients with unresectable metastatic disease were excluded of the referral. Key performance indicators were also agreed including the time to referral and completion of pelvic MRI-, CT-, PET-scan prior to MDT referral.
CONCLUSION
The development of this referral pathway represents an innovative health service, which will improve the management of patients with LRRC in France.

Identifiants

pubmed: 31866109
pii: S0748-7983(19)31494-5
doi: 10.1016/j.ejso.2019.12.001
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

470-475

Informations de copyright

Copyright © 2019 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Quentin Denost (Q)

Department of Digestive Surgery, Haut-leveque Hospital, Bordeaux University Hospital, Pessac, France. Electronic address: quentin.denost@chu-bordeaux.fr.

Veronique Bousser (V)

Aquitaine Regional Cancer Network, 33076, Bordeaux, France. Electronic address: veronique.bousser@onco-na.fr.

Claire Morin-Porchet (C)

Onco-Poitou-Charentes Network, 86000, Poitiers, France. Electronic address: claire.morin-porchet@onco-na.fr.

Cecile Vincent (C)

Limousin Oncology-Hematology Network (ROHLim), 87000, Limoges, France. Electronic address: cecile.vincent@rohlim.fr.

Elodie Pinon (E)

Aquitaine Regional Cancer Network, 33076, Bordeaux, France. Electronic address: elodie.pinon@onco-na.fr.

Fideline Collin (F)

Department of Digestive Surgery, Haut-leveque Hospital, Bordeaux University Hospital, Pessac, France. Electronic address: fideline.collin@chu-bordeaux.fr.

Aurelie Martin (A)

INSERM, ISPED, Centre INSERM U1219-Bordeaux Population Health, Team EMOS, F-33000, Bordeaux, France. Electronic address: aurelie.martin@chu-bordeaux.fr.

Françoise Colombani (F)

Bordeaux University Hospital-CHU Bordeaux, F-33000, Bordeaux, France. Electronic address: francoise.colombani@chu-bordeaux.fr.

Laurence Digue (L)

Department of Medical Oncology, Saint-André Hospital, Bordeaux University Hospital-CHU Bordeaux, France; Aquitaine Regional Cancer Network, 33076, Bordeaux, France. Electronic address: laurence.digue@chu-bordeaux.fr.

Alain Ravaud (A)

Department of Medical Oncology, Saint-André Hospital, Bordeaux University Hospital-CHU, Bordeaux, France, University of Bordeaux, Bordeaux, France. Electronic address: alain.ravaud@chu-bordeaux.fr.

Deena Pravin Harji (DP)

Department of Digestive Surgery, Haut-leveque Hospital, Bordeaux University Hospital, Pessac, France. Electronic address: deena_harji@hotmail.com.

Florence Saillour-Glénisson (F)

INSERM, ISPED, Centre INSERM U1219-Bordeaux Population Health, Team EMOS, F-33000, Bordeaux, France. Electronic address: florence.saillour@chu-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH